Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of BI 44370 on Midazolam PK
NCT02217514Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2008
- Primary completion
- Mar 2008
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of BI 44370 in migraine (5 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum concentration of midazolam in plasma up to 24 hours, Area under the concentration-time curve of midazolam in plasma from 0 to last quantifiable data point up to 24 hours and 1 more. Started Feb 2008; status: completed.
02
Drugs
BI 44370
03
Conditions
migraine
Beyond the preview
Go deeper on NCT02217514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02217514.